Details for New Drug Application (NDA): 050590
✉ Email this page to a colleague
NDA 050590 describes TIMENTIN, which is a drug marketed by Glaxosmithkline and is included in three NDAs. Additional details are available on the TIMENTIN profile page.
The generic ingredient in TIMENTIN is clavulanate potassium; ticarcillin disodium. There are twenty-seven drug master file entries for this compound. Additional details are available on the clavulanate potassium; ticarcillin disodium profile page.
The generic ingredient in TIMENTIN is clavulanate potassium; ticarcillin disodium. There are twenty-seven drug master file entries for this compound. Additional details are available on the clavulanate potassium; ticarcillin disodium profile page.
Summary for 050590
| Tradename: | TIMENTIN |
| Applicant: | Glaxosmithkline |
| Ingredient: | clavulanate potassium; ticarcillin disodium |
| Patents: | 0 |
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | INJECTABLE;INJECTION | Strength | EQ 100MG BASE/VIAL;EQ 3GM BASE/VIAL | ||||
| Approval Date: | Apr 1, 1985 | TE: | RLD: | No | |||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | INJECTABLE;INJECTION | Strength | EQ 200MG BASE/VIAL;EQ 3GM BASE/VIAL | ||||
| Approval Date: | Apr 1, 1985 | TE: | RLD: | No | |||||
Profile for product number 003
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | INJECTABLE;INJECTION | Strength | EQ 1GM BASE/VIAL;EQ 30GM BASE/VIAL | ||||
| Approval Date: | Aug 18, 1987 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
